Search Results

FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases.

Rivus Pharmaceuticals will push HU6 into Phase III development and is looking to engage with regulatory authorities and launch a late-stage study next year in obesity-related heart failure with preserved ejection fraction.

Compugen Ltd. announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced an oral presentation on the company’s proprietary AURIGIN™ platform at the AI in Biomedicine Keystone Symposia held May 1-3, 2024.

Natera, Inc. today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.

Endotronix, Inc. today announced Premarket Approval (PMA) from the U.S Food and Drug Administration (FDA) of the company’s Cordella™ Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients.

OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood pressure monitor with ECG technology, Complete, and a series of home-use blood pressure monitors.